Cephalon (Nasdaq: CEPH) is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat human diseases. Currently its four core therapeutic areas are central nervous system disorders, pain, cancer and addiction.
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system (“CNS”), pain, oncology, and their latest area of focus, inflammatory diseases. In addition to conducting an active research and development program, they market seven proprietary products in the United States and numerous products in various countries throughout Europe and the world. Consistent with their core therapeutic areas, Cephalon has aligned their approximately 780-person U.S. field sales and sales management teams by area. They have a sales and marketing organization numbering approximately 400 persons that supports their presence in nearly 20 European countries, including France, the United Kingdom, Germany, Italy and Spain, and certain countries in Africa and the Middle East.
Source: Cephalon May 6th, 2009 10-Q